Tumor-infiltrating lymphocytes show ‘remarkable’ results in advanced melanoma

Source: Healio, June 2020

Lifileucel induced high response rates among patients with advanced melanoma whose disease progressed on immune checkpoint and BRAF/MEK inhibitors, according to study results presented during the ASCO20 Virtual Scientific Program.

The cell-based therapy also had an acceptable safety profile, results of the phase 2 study showed.

Lifileucel (LN-144, Iovance Biotherapeutics) is an investigational adoptive cell therapy that uses genetically engineered autologous tumor-infiltrating lymphocytes (TILs) to treat patients with advanced melanoma that progressed despite multiple previous therapies.

READ THE ORIGINAL FULL ARTICLE